Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Common Equity: 2021-2025

Historic Common Equity for Roivant Sciences (ROIV) over the last 5 years, with Mar 2025 value amounting to $5.2 billion.

  • Roivant Sciences' Common Equity fell 13.88% to $4.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 billion, marking a year-over-year decrease of 13.88%. This contributed to the annual value of $5.2 billion for FY2025, which is 19.56% down from last year.
  • According to the latest figures from FY2025, Roivant Sciences' Common Equity is $5.2 billion, which was down 6.30% from $5.5 billion recorded in FY2024.
  • In the past 5 years, Roivant Sciences' Common Equity registered a high of $6.6 billion during FY2023, and its lowest value of $1.4 billion during FY2022.
  • For the 3-year period, Roivant Sciences' Common Equity averaged around $5.1 billion, with its median value being $5.5 billion (2024).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 36.49% in 2022, then skyrocketed by 361.38% in 2023.
  • Yearly analysis of 5 years shows Roivant Sciences' Common Equity stood at $2.0 billion in 2021, then reached $2.2 billion in 2021, then dropped by 0.03% to $2.0 billion in 2022, then slumped by 36.49% to $1.4 billion in 2022, then dropped by 21.16% to $1.6 billion in 2023, then skyrocketed by 361.38% to $6.6 billion in 2023, then spiked by 301.13% to $6.4 billion in 2024, then declined by 15.93% to $5.5 billion in 2024, then declined by 19.56% to $5.2 billion in 2025.